Micro RNAs are small non-coding RNAs, which regulate fundamental cellular and developmental processes at the transcriptional and translational level. In breast cancer, miR-145 expression is downregulated compared with healthy control tissue. As several predicted targets of miR-145 potentially regulate cell motility, we aimed at investigating a potential role for miR-145 in breast cancer cell motility and invasiveness. Assisted by Affymetrix array technology, we demonstrate that overexpression of miR-145 in MDA-MB-231, MCF-7, MDA-MB-468 and SK-BR-3 breast cancer cells and in Ishikawa endometrial carcinoma cells leads to a downregulation of the cell-cell adhesion protein JAM-A and of the actin bundling protein fascin. Moreover, podocalyxin and Serpin E1 mRNA levels were downregulated, and gamma-actin, transgelin and MYL9 were upregulated upon miR-145 overexpression. These miR-145-dependent expression changes drastically decreased cancer cell motility, as revealed by time-lapse video microscopy, scratch wound closure assays and matrigel invasion assays. Immunofluorescence microscopy demonstrated restructuring of the actin cytoskeleton and a change in cell morphology by miR-145 overexpression, resulting in a more cortical actin distribution, and reduced actin stress fiber and filopodia formation. Nuclear rotation was observed in 10% of the pre-miR-145 transfected MDA-MB-231 cells, accompanied by a reduction of perinuclear actin. Luciferase activation assays confirmed direct miR-145-dependent regulation of the 3 0 UTR of JAM-A, whereas siRNA-mediated knockdown of JAM-A expression resulted in decreased motility and invasiveness of MDA-MB-231 and MCF-7 breast cancer cells. Our data identify JAM-A and fascin as novel targets of miR-145, firmly establishing a role for miR-145 in modulating breast cancer cell motility. Our data provide a rationale for future miR-145-targeted approaches of antimetastatic cancer therapy.
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Introduction
MicroRNAs are endogenous small non-coding RNAs. Cleavage of microRNA precursors by the RNase enzyme complex, Drosha-DGCR8 is followed by the action of cytoplasmic RNase III Dicer to generate duplexes of approximately 19-25 nucleotides (Hutvagner et al., 2001; Lee et al., 2003) . One duplex strand is degraded whereas the other strand is incorporated into RNA-induced silencing complex. MicroRNAs bind to partially complementary target sites in the 3 0 untranslated region of target messenger RNAs, leading to translational repression of the encoded protein or mRNA degradation (Bartel, 2004) . MicroRNAs have emerged as regulators of gene expression in critical cellular processes such as differentiation, apoptosis and stem cell renewal (Baehrecke, 2003; Bartel, 2004; Xu et al., 2009) .
In breast cancer, dysregulated microRNA expression is associated with tumor initiation, progression and metastasis (Iorio et al., 2005; Ma et al., 2007) . The microRNA miR-145 is downregulated in clinical samples of breast cancer and breast cancer cell lines relative to normal breast tissue (Iorio et al., 2005; Sempere et al., 2007; Wang et al., 2009) . Expression of miR-145 is restricted to the myoepithelial/basal cell compartment of normal mammary ducts and lobules, whereas expression is reduced or completely eliminated in matching tumor specimens, suggesting that early manifestation of altered miR-145 expression in atypical hyperplasia and carcinoma in situ lesions may have a potential clinical application as a novel biomarker for early detection (Sempere et al., 2007) . Mechanistically, early changes in miR-145 expression may be linked to its role in modulating apoptosis: For example, miR-145 overexpression in MCF-7 breast cancer cells inhibits rhotekin expression, resulting in increased apoptosis and reduced cell proliferation . Furthermore, ectopic expression of miR-145 in lung cancer Sempere et al., 2009 ) and colon cancer cell lines (Takagi et al., 2009 ) increases apoptosis. Apparently, the pro-apoptotic effect of miR-145 depends on TP53 activation (Spizzo et al., 2010) and may involve a caspase-independent pathway (Ostenfeld et al., 2010) . Taken together, miR-145 functions as a potential tumor suppressor. In line with this hypothesis, the tumor suppressor p53 enhances post-transcriptional maturation of miR-145 in response to DNA damage (Suzuki et al., 2009) . p53 transcriptionally induces miR-145 expression by interacting with a potential p53 response element in its promoter (Sachdeva et al., 2009 ), leading to a modulation of c-Myc expression by miR-145. Specific silencing of c-Myc accounts at least in part for the miR-145-mediated inhibition of breast cancer cell growth in vivo and in vitro (Sachdeva et al., 2009; Sachdeva and Mo, 2010) . Part of the enhancement of the invasive phenotype of breast cancer cells by miR-145 was attributed to miR-145-dependent translational regulation of mucin-1, a glycoprotein that can help the tumor cell to escape immunosurveillance (Sachdeva and Mo, 2010) .
As recent reports have established a role for miR-145 in modulating smooth muscle cell motility and differentiation (Cheng et al., 2009; Cordes et al., 2009; Larsson et al., 2009; Xin et al., 2009; Zeng et al., 2009) , we aimed at investigating a potential role for miR-145 in the regulation of breast cancer cell motility in vitro. We demonstrate that restoration of high miR-145 expression levels in a panel of human breast cancer cell lines and an endometrial carcinoma cell line leads to inhibition of JAM-A, a membrane protein involved in cell-cell adhesion and cell motility regulation, and to downregulation of the actin-bundling protein fascin. Targeting of these structures resulted in inhibition of MDA-MB-231 breast cancer cell invasiveness, in restructuring of the actin cytoskeleton and in a massive inhibition of cell motility. Our data suggest a novel fundamental mechanism of cell motility regulation by miR-145, with translational implications for breast and endometrial cancer pathogenesis.
Results
Upregulation of miR-145 inhibits MDA-MB-231 breast cancer cell motility and invasiveness miR-145 expression is downregulated in breast cancer tissue (Iorio et al., 2005) , and loss of miR-145 expression is associated with tumor progression (Sempere et al., 2007) . Therefore, we hypothesized that restoring high miR-145 expression in breast cancer cells may induce a more benign phenotype through downregulation of key molecules involved in breast cancer pathogenesis. We increased miR-145 expression in a panel of wellestablished breast cancer cell lines of varying degree of de-differentiation and malignant potential (Lacroix and Leclercq, 2004) , and in an endometrial carcinoma cell line (Ishiwata et al., 1984) by transient microRNA precursor transfection to study the impact of miR-145 overexpression on cell proliferation, motility and invasiveness. miR-145 expression was determined by quantitative real-time PCR in the cell lines MCF-7 (luminal-epithelial-like, estrogen-receptor positive (ER þ ), weakly invasive in vitro), SK-BR-3 (weakly luminal epithelial-like, ERÀ, weakly invasive), MDA-MB-468 (weakly luminal epithelial-like, intermediate invasiveness, ERÀ, forms tumors in nude mice), MDA-MD-231 (mesenchymal morphology, ERÀ, highly invasive and tumorigenic in nude mice) and Ishikawa (endometrial carcinoma, weakly invasive). miR-145 expression increased in the order MDA-MB-231oMCF-7oIshikawa oSK-BR-3oMDA-MB-468, as reflected by successively decreasing DCt-values ( Figure 1a ). miR-145 expression was increased 10 3 -fold (MCF-7) to 4 Â 10 4 -fold (MDA-MB-231) 3 days after pre-miR-145 precursor transfection (Figure 1b) , and already substantially increased 48 h after transfection (Supplementary Figure S1) . In MDA-MB-231 cells, representing the aggressive spectrum of our cancer cell panel, proliferation was not altered by miR-145 transfection over a time course of 48-96 h post transfection (Figure 1c) , however, in vitro matrigel invasiveness was inhibited by 40% (Figure 1d ). miR-145 upregulation delayed the ability of MDA-MB-231 cells to close a scratch wound (Figure 1e ), suggesting a role of miR-145 in regulating breast cancer cell motility.
Upregulation of miR-145 in breast and endometrial carcinoma cell lines leads to differential regulation of fascin, JAM-A and cytoskeletal elements In silico analysis of miRbase (Griffiths-Jones et al., 2006) and DIANA miRGen (Megraw et al., 2007) database entries identified 4500 predicted mRNA targets of miR-145. To screen for miR-145-regulated candidate genes in our system, we compared the transcriptome of miR-145-overexpressing MDA-MB-231 cells against that of control miRNA precursortransfected cells using Affymetrix U133v2 Gene Arrays. 22 downregulated and 8 upregulated annotated genes satisfied the filtering criteria of Po0.05 and fold change X1.5. Based on their gene ontology groupings, several genes were likely involved in the observed phenotypic changes (Table 1 and Supplementary Figure S2 ): JAM-A, a cell-cell adhesion molecule linked to breast cancer metastasis (Naik et al., 2008; McSherry et al., 2009) , the actin bundling protein fascin, a modulator of cell motility (Vignjevic et al., 2007; Darnel et al., 2009; Kim et al., 2009b; Qualtrough et al., 2009) , podocalyxinlike (PODXL), mediating cell migration (Sizemore et al., 2007; Larrucea et al., 2008) , and the protease inhibitor serpin E (PAI-1) (Nikolova et al., 2009) were downregulated upon pre-miR-145 transfection, whereas actin gamma 2, transgelin and myosin-9 mRNA were upregulated. miRbase and miRGen searches identified Figure 3a ). Single-transfection of MDA-MB-231 cells with the antimiR-145 inhibitor resulted in a significant, yet quantitatively modest increase in a JAM-A (25%, P ¼ 0.02), fascin (27%, P ¼ 0.02) and myosin 9 (45%, P ¼ 0.01) expression, whereas actin gamma 2 and transgelin expression did not change (Supplementary Figure S3) .
JAM-A is a direct target of transcriptional regulation by miR-145
A direct regulation of the 3 0 UTR of fascin by miR-145 has previously been demonstrated in bladder cancer (Chiyomaru et al., 2010) , esophageal squamous cell carcinoma (Kano et al., 2010) and 3T3 cells (Quintavalle miR-145 overexpression results in a restructuring of the actin cytoskeleton, a shift in the structural index, nuclear rotation and a reduction of the migratory speed and translocation We next employed time-lapse and immunofluorescence microscopy to analyze miR-145-dependent effects on cell motility and cytoskeletal structure in detail. miR-145 miR-145 in breast cancer cell motility and invasiveness M Götte et al overexpression in MDA-MB-231 cells led to a highly significant reduction of (i) migratory speed by 480% and (ii) their translocation over 12 h by 485% ( Figure 5 and Supplementary Videos 1 and 2). Apart from reversing the effect of pre-miR-145, treatment with an antimiR-145 inhibitor significantly increased migratory speed to 1.6-fold, and translocation to 2.37-fold ( Figure 5) . Analysis of the structural index (Supplementary miR-145 in breast cancer cell motility and invasiveness M Götte et al Figure S5 ) and phalloidin-staining (Figures 6a-e ) demonstrated that restoration of high miR-145 expression deterred the MDA-MB-231 cells from spreading out completely, leading to a rather spherical shape. The structural index was also increased by miR-145 inhibition (Supplementary Figure S5) . The changes in cell motility led to a clear reduction of the area explored by pre-miR-145-transfected cells, and to a significant increase upon antimiR-145 transfection (Figure 5c ). pre-miR-145 transfection induced a massive restructuring of the actin cytoskeleton, characterized by a more cortical distribution of actin filaments, reduced numbers of actin stress fibers and of filopodia ( Figure 6 ). In contrast, approximately 10% of the pre-miR-145-treated cells showed a rotation of the cell nuclei ( Figure 6f, Supplementary Video 3) , a phenotype possibly linked to reduced perinuclear actin ( Figure 6) (Naik et al., 2008) . Comparing our data with the study by Naik et al. (2008) , we conclude that differences in the experimental conditions may have contributed to the seemingly contradictory data: (i) In their invasion assays, Naik et al. plated the cells at low density (1.000 cells/filter), whereas cells were plated at much higher density (25.000 cells/filter) in our study, allowing cells to establish cell-cell contact, as controlled by light microscopy. Considering the role of JAM-A as a cell-cell adhesion molecule, this difference is of major importance, as JAM-A may be capable of mediating signalling through homotypic interactions under our experimental conditions. (ii) Our matrigel invasion assays were performed using matrigel preparations, which contained growth factors, whereas Naik et al. used growth-factor depleted matrigel. Thus, in our study, the role of JAM-A in growth-factor-mediated signalling (Naik et al., 2003) may have contributed to the modulation of cell motility. Although our data are in line with the majority of published studies, suggesting an inhibition of cell motility and invasiveness upon loss of JAM-A function (Naik et al., 2003; Cera et al., 2009; McSherry et al., 2009; Severson et al., 2009) , they also show that JAM-A function is context-dependent, and may be modulated by the presence or absence of cellcell-contact and growth factors, integrin expression patterns and matrix substrates. In addition to JAM-A, miR-145-dependent regulation of fascin may have contributed to the migratory phenotype. Fascin bundles lamellopodial actin filaments into filopodia (Hashimoto et al., 2007) , and is a direct target of miR-145 in bladder cancer, esophageal squamous cell carcinoma and 3T3 cells (Chiyomaru et al., 2010; Kano et al., 2010; Quintavalle et al., 2010) . Increased fascin expression enhances, and decreased expression reduces cell motility in esophageal squamous cell, gastric, prostate and colorectal cancer (Vignjevic et al., 2007; Darnel et al., 2009; Kim et al., 2009b; Qualtrough et al., 2009; Kano et al., 2010) , and correlates with metastasis (Darnel et al., 2009) . Moreover, fascin promotes tumor self-seeding by circulating miR-145 in breast cancer cell motility and invasiveness M Götte et al cancer cells (Kim et al., 2009a) . In breast cancer, high fascin expression has been suggested to be associated with a more aggressive clinical course (Yoder et al., 2005) . In our experimental system, loss of fascin expression contributed to decreased cellular motility and a restructuring of the actin cytoskeleton. Similarly, fascin-depletion altered colon carcinoma cell protrusion morphology, and decreased (i) the numbers of filopodia, (ii) Rac-dependent migration on laminin, (iii) turnover of focal adhesions and (iv) tumor development and metastasis in vivo (Hashimoto et al., 2007) . In accordance with the cytoskeletal restructuring demonstrated by our study, miR-145-dependent regulation of fascin expression was suggested to modulate podosome formation in vascular smooth muscle cells (Quintavalle et al., 2010) , with implications for the regulation of cell motility.
Smooth muscle actin and myosin isoforms are upregulated by miR-145 in rat vascular smooth muscle cells (Cheng et al., 2009) and zebrafish intestinal smooth muscle cells ), due to negative regulation of KLF5 and GATA6. Similarly, actin gamma 2, transgelin and myosin-9 mRNA were upregulated in our study. In accordance with our in vitro wound repair data, neointima formation in response to vascular injury was impeded in mice lacking miR-145 and miR-143, due to disarray of actin stress fibers and reduced smooth muscle cell migration (Xin et al., 2009) . Similarly, targeting of the transcription factor Fli1 by miR-145 reduced migration of microvascular cells (Larsson et al., 2009) . As control experiments confirmed that b-actin and MLC2 were not differentially expressed, we conclude that the strongly regulated targets JAM-A and fascin are major contributors to the cytoskeletal phenotype. miR-145 overexpression induced nuclear rotation. Numerous cellular and developmental processes, including cell migration, cell division and cell polarity, depend miR-145 in breast cancer cell motility and invasiveness M Götte et al on specific positioning of the nucleus (Gomes et al., 2005; Levy and Holzbaur, 2008) . F-actin partially impeded nuclear rotation in vimentin-deficient cells (Gerashchenko et al., 2009) , and actin stress fiber disruption stimulates nuclear rotation in fibroblasts (Levy and Holzbaur, 2008) , suggesting that actinnuclear connections or actin stress fibers may dampen dynein driven rotations (Gomes et al., 2005) . Our data establish a novel function for a specific microRNA in this process. PODXL is abnormally expressed in breast cancer subsets (Sizemore et al., 2007; Larrucea et al., 2008) . In accordance with our data, its overexpression increased MCF-7 cell migration and invasion (Sizemore et al., 2007) , and CHO cell migration during in vitro wound healing (Larrucea et al., 2008) .
Two miR-145 targets identified in our Affymetrix screening were recently characterized: Overexpression of miR-145 in MCF-7 cells inhibited rhotekin expression, resulting in growth retardation and apoptosis ). Whereas we demonstrated downregulation of mucin 5AC, mucin-1 was identified as a miR-145-target, which modulates breast cancer cell invasiveness and lung metastasis in a xenograft model (Sachdeva and Mo, 2010) . Our data strongly suggest that mucin-1 is not the only miR-145 target with relevance for breast cancer cell invasiveness, because the breakdown of the actin cytoskeleton and JAM-A downregulation severely impaired breast cancer cell motility.
Therefore, miR-145 appears to act as a tumor suppressor at different stages of breast cancer progression: miR-145 loss is observed already in hyperplastic lesions in the breast at a time point before the actual penetration through the lamina propria and migration through the extracellular matrix (Sempere et al., 2007) miR-145 in breast cancer cell motility and invasiveness M Götte et al Ostenfeld et al., 2010) . However, our data and the study by Sachdeva and Mo (2010) suggest that loss of miR-145 also affects later stages of tumor progression by modulating metastasis, the major cause of breast cancerrelated deaths (Weigelt et al., 2005) . From a clinical perspective, this may be particularly important if a tumor has acquired apoptosis resistance, as exemplified by our proliferation data in MDA-MB-231 cells: Mechanistically, miR-145 is not capable of modulating MDA-MB-231 proliferation and apoptosis because of a TP53 mutation and an ERÀ status (Spizzo et al., 2010) .
Our findings open an important translational perspective: restoration of miR-145 expression in breast cancer cells in vivo is a multitargeted approach, based on inhibition of tumor cell proliferation in ER þ breast cancers (Spizzo et al., 2010) , induction of apoptosis , silencing of c-Myc (Sachdeva et al., 2009 ) and on its antimetastatic activity through interference with fascin, JAM-A, PODXL, SERPIN E, mucin-1 and possibly mucin 5AC. A cancer stem cell phenotype may be suppressed through downregulation of pluripotency-associated transcription factors Go¨tte, 2010) . Decreased expression of multidrug resistance proteins associated with this phenotype may be the reason for increased sensitivity to chemotherapeutics in gastric cancer cells transfected with pre-miR-145 (Takagi et al., 2009) . Technically, the future application of locked nucleic acid-derivatives of pre-miR-145 in pre-clinical and clinical settings may represent less of a challenge than expected, as Elme´n et al. (2008) demonstrated safe and efficient in vivo effects of locked nucleic acid-antimiR treatment in a nonhuman primate model. Similar applications can be envisaged for miR-145 targeting reagents in anticancer therapy in the not too distant future.
Materials and methods

Materials
Media, fetal calf serum and tissue culture supplies were from Gibco BRL (Karlsruhe, Germany). Unless stated otherwise, all chemicals were from Sigma (Deisenhofen, Germany).
Cell culture, microRNA and siRNA transfection MDA-MB-231, MDA-MB-468, MCF-7 and SK-BR-3 cells (Lacroix and Leclercq, 2004) were obtained from ATCC/LGC Promochem (Wesel, Germany). Ishikawa cells (Ishiwata et al., 1984) were provided by Dr A Starzinski-Powitz, Frankfurt a.M., Germany. MDA-MB-231, MDA-MB-468 and Ishikawa cells were maintained in DMEM containing 10% fetal calf serum, 1% glutamine and 1% penicillin-streptomycin in a humidified atmosphere of 8.5% CO 2 at 37 1C. MCF-7 and SK-BR-3 cells were maintained in RPMI 1640 containing 10% fetal calf serum, 1% glutamine and 1% penicillin-streptomycin in a humidified atmosphere of 5% CO 2 at 37 1C. For microRNA and siRNA studies, cells were plated in six-well plates 1 day before transfection to reach 70% confluency after 24 h. Transfection was performed using Dharmafect reagent (Dharmacon, Lafayette, CO, USA) in OPTI-MEM media (Gibco) and microRNA precursor miR-145 (10 nM), pre-miR precursor negative control #1 (10 nM), anti-miR micro RNA inhibitor miR-145 (20 nM), JAM-A siRNA s27151 (40 nM) (Applied Biosystems (ABI), Darmstadt, Germany), or a plasmid encoding human JAM-A cDNA lacking its endogenous 3 0 UTR according to the manufacturers instructions. The eukaryotic expression construct encoding human JAM-A (amino acids 26-299) with an N-terminal Flag-tag (Ebnet et al., 2001 ) was generated in pFLAG-cytomegaly virus-1 (Sigma-Aldrich, Deisenhofen, Germany). After 24 h of transfection, OPTI-MEM was replaced by regular culture medium. Functional and expression analyses were performed 48-72 h after transfection. Details on lentivirus-mediated expression of a human JAM-A shRNA construct can be found in Supplementary Information.
Luciferase assays
To investigate transcriptional regulation of JAM-A expression by miR-145, pre-miR-145 was co-transfected along with 1 mg of plasmid pEZX-MT01 expressing firefly luciferase under the control of the human JAM-A 3 0 UTR, and renilla luciferase under the control of the cytomegaly virus promoter (HmiT012239, GeneCopoeia, Rockville, MD, USA) essentially as described above. Luciferase assays were performed in quadruplets (n ¼ 3 experiments) in a 96-well format using the Luc-Pair miR Luciferase Assay (GeneCopoeia) exactly as described by the manufacturer. At 72 h after transfection, cell lysates were prepared and assayed in a luminometer normalizing firefly to renilla luciferase activity measured in the same well. Data were expressed as percent inhibition relative to control miR-transfected cells.
RNA isolation and reverse transcription microRNA and mRNA isolation from cultured cells were performed simultaneously using the mirVana miRNA Isolation Kit (ABI) following the manufacturer's instructions. microRNA was converted into cDNA using the TaqMan MicroRNA Reverse Transkription kit (ABI). Reverse transcription of mRNA was performed using the First strand cDNA Synthesis kit (Fermentas, St Leon Rot, Germany).
Quantitative TaqMan real-time PCR analysis cDNA corresponding to 0.5 ng total RNA was used as a template in the PCR reaction consisting of (ABI) Master-Mix and the following pre-designed TaqMan gene expression systems (ABI): Hs00170991_m1, Hs00602051_m1, Hs01123712_m1, Hs01574644_m1, Hs00697086_m1, Hs00162558_m1 and Hs01126607_g1. Target gene expression was normalized to 18S rRNA expression (Hs99999901_s1). microRNA expression was determined using TaqMan microRNA assays miR-145 and RNU6B (ABI). Quantitative real-time PCR was performed using the ABI PRISM 7300 sequence detection system by using the default thermal cycling conditions. Relative quantitation was performed using the comparative cycle threshold method.
Affymetrix microarray expression analysis
Transcriptome analysis using Affymetrix microarrays (Affymetrix, Santa Clara, CA, USA) was carried out as previously described (Nikolova et al., 2009) . A detailed description is provided in the Supplementary Information. The GEO accession number of this screening is GSE19737.
Western blotting
Western blotting of cell extracts was performed exactly as previously described (Nikolova et al., 2009 ) using mouse-antihuman fascin (clone 55K-2, 1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse-anti human JAM-1 (JAM-A) miR-145 in breast cancer cell motility and invasiveness M Götte et al
(1:500, Becton Dickinson, Heidelberg, Germany) and mouseanti human tubulin (1:4000, Sigma) as primary antibodies, and HRP-labeled goat-anti mouse IgG (1:10 000, Calbiochem, Darmstadt, Germany) as a secondary antibody. Cell extracts were prepared 72 h after transfection.
Cell proliferation assay
Cell proliferation was determined by MTT assay as described previously (Seidler et al., 2006) . 48, 72 or 96 h after microRNA precursor transfection, 10 000 MDA-MB-231 cells were seeded in 96-well plates and cultured for 24 h, followed by 24 h incubation in the presence of MTT, lysis and optical density measurement at 595 nm in a microplate reader.
Scratch wound assay
Scratch wound assays were performed essentially as described (Go¨tte et al., 2008) . At 72 h after pre-miR or siRNA transfection, confluent MDA-MB-231 monolayers were wounded by scraping once horizontally and vertically with a 100 ml pipet tip. Closing of the scratch wound was monitored by Nomarksi contrast light microscopy and documented with a Zeiss Axiophot camera (Zeiss, Go¨ttingen, Germany) immediately and 6, 10 and 24 h after wounding. Zeiss Axiovision software (Zeiss) was used to calculate the cell-free wounded area.
Matrigel invasion assay
Matrigel invasion chamber assays were performed essentially as described (Nikolova et al., 2009) , plating 25.000 cells/ invasion filter 24 h after pre-miR transfection for 24 h, followed by performing the invasion assay by addition of 10% fetal calf serum containing media for an additional 24 h (MDA-MB-231) or 48 h (MCF-7), respectively.
Time-lapse and immunofluorescence microscopy Time-lapse microscopy experiments were essentially performed as described previously (Stu¨we et al., 2007) . A detailed description of time-lapse microscopy experiments is available in the Supplementary Information. Visualization of actin filaments using ALEXA-Fluor 568-labelled phalloidin (1:1000 Invitrogen, Karlsruhe, Germany) was performed exactly as described previously (Go¨tte et al., 2008) . Images were acquired at 20 1C using an Olympus BX6 fluorescence microscope ( Â 60 Olympus UPSAPO oil immersion objective, n.a. ¼ 1.35) equipped with a Retiga 4000R camera and Qcapture software. Single color images were merged using Adobe Photoshop software. Images were adjusted for brightness without performing gamma adjustments.
Statistics
All experiments were repeated at least three times in triplicates. Data are presented as the mean values±s.e.m. The data were tested for significance employing Student's unpaired t-test. The level of significance was set at Po0.05 except where stated otherwise.
